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Abstract The objectives of this article are to assess the
frequency and signiWcance of facial paralysis and undiag-
nosed nerve inWltration in patients with parotid malignan-
cies. 103 patients with parotid gland malignancies were
treated in a single institution, the tertiary center for ENT at
the University Department in Poznan between 1996 and
2006. Facial palsy at the initial presentation was found in
32 patients. The stage of the primary tumor in the examined
group of 103 patients is as follows: 20—T1, 31—T2, 20—T3,
32—T4. The correlation between facial nerve function
before treatment and patients’ characteristics, including the
treatment methods, were analyzed. Intact facial nerve func-
tion at patient presentation was a very strong prognostic
factor determining the treatment and Wnal outcome for
malignant neoplasms of parotid gland. Similarly, T stage
and a high-grade malignant histology had a direct inXuence
on the duration of patients’ survival.
Keywords Parotid malignant tumors · Facial nerve 
paralysis
Introduction
Parotid tumors typically manifest as a painless lump in the
preauricular region. The majority are benign; however,
inXammatory symptoms (pain, reddened skin) and facial
asymmetry are characteristics that strongly suggest a malig-
nant lesion. The duration of complaints in such a histologi-
cally diverse group of benign tumors and malignancies can
vary greatly. Facial nerve weakness alarms the patient,
family, and General Practitioner and prompts an earlier
referral and consultation. Preoperative facial nerve palsy is
a manifestation of malignant inWltration and so far, the only
preoperative indicator for planning total parotidectomy
with nerve resection and facial reanimation [3,  6,  15].
When the facial nerve function is intact, early involvement
with tumor cannot be deWnitively ruled out. Preoperative
imaging (ultrasonography, computed tomography, and
magnetic resonance) do not have the resolution for nerve
structure visualization [5]. Therefore, intraoperative nerve
assessment is crucial in the decision making process as to
whether the nerve should be resected.
The aims of the study are to (1) assess the frequency of
facial paralysis and undiagnosed nerve inWltration in
patients with parotid malignancies; (2) analyze the duration
of symptoms before presentation; and (3) deWne the risk
factors for nerve impairment and the impact of facial nerve
involvement on treatment methods, outcomes, and survival.
Materials
One hundred and three patients had surgery for parotid
gland malignancies in a single institution, the tertiary center
for ENT as the University Department in Poznaj between
1996 and 2006. Facial palsy, assessed in House–Brack-
mann 6-score scale (H-B), was identiWed at the initial pre-
sentation in 32 patients: 28 had total facial palsy (H-B 6)
and 4 had partial facial palsy (H-B 2-5). In Wve other patients,
intra-operative features of facial nerve inWltration were found
although the facial mobility was normal preoperatively
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(H-B 1). The study group included 53 women and 50 men
ranging in age from 12 to 87 years, with a mean age of
55 years.
The tumor histology was assessed according to
WHO—1991 classiWcation, modiWed in 2003: adenoid cystic
carcinoma—27, acinic cell carcinoma —9, undiVerentiated
carcinoma—8, mucoepidermoid carcinoma—8, squamous
cell carcinoma—18, anaplastic carcinoma—3, adenocarci-
noma—7, lymphoma malignum—5, ex-pleomorphic carci-
noma—6, and metastases—12. Twelve cases assessed on
the base of histology as metastases had primaries in: skin
(two malignant melanoma), kidney (two clarocellular cancer),
prostatic gland (two adenocarcinoma), and upper aerodi-
gestive tract (six squamous cell carcinoma). In preoperative
oligobiopsy atypical cell or malignant cell were diagnosed
in all cases from “metastases group.” Thus, these patients
were primarily graded with T stage. Finally, 2 weeks after the
procedure, the pathological examination revealed metastases
and the further diagnostics of the primary was carried up.
We would underline the diVerence between primary salivary
tumors and metastatic process. In further analysis, this group
would be distinguished and its outcomes compared with
other histological entities.
The stage of the primary tumor in the examined group of
103 patients is as follows: 20—T1, 31—T2, 20—T3,
32—T4a. The diameter of the tumors in preoperative imaging
(ultrasonography, computed tomography, or magnetic reso-
nance imaging) ranged from 1 to 9 cm, with a mean 3 cm.
The duration of symptoms before the initial presentation
ranged between 1 and 120 months, with a mean of
12 months. The mean duration of complaints in patients
with facial palsy was 16.8 months and the mean duration of
complaints in patients without facial palsy was 14.1 months.
The duration of complaints for a particular histologic diagnosis
was as follows: adenoid cystic carcinoma—15 months, acinic
cell carcinoma—7 months, undiVerentiated carcinoma—7
months, mucoepidermoid carcinoma–15 months, squamous
cell carcinoma—6 months, and adenocarcinoma—34 months.
Taking into consideration the cancer histology, facial
nerve paresis was noted in: 11 out of 27 with adenoid cys-
tic, 5 out of 9 with acinic cell, 4 out of 8 with undiVerenti-
ated, 3 out of 8 with mucoepidermoid, 6 out of 18 with
squamous cell, 4 out of 6 with ex-pleomorphic cancer, 1 out
of 7 with adenocarcinoma, and in 0 out of 20 patients from
the rest of the group (12 with metastases in parotid, 5 with
lymphoma malignum, and 3 with anaplastic carcinoma).
All patients were treated surgically with the intent
for complete resection. In most cases, the facial nerve
was identiWed by anterograde dissection, but in some it
was identiWed by the retrograde technique. A cable graft,
when used, was harvested from the greater auricular
nerve. All patients with nerve palsy were given adjuvant
radiotherapy.
The data were analyzed statistically by Chi-square test to
compare categorical variables between groups or non-para-
metric Kruskal–Wallis and Mann–Whitney test. The over-
all survival results were calculated using the Kaplan–Meier
method and diVerences were analyzed by the log-rank test.
Results
The correlation between facial nerve function before treat-
ment and patients’ characteristics, including the treatment
methods, were analyzed.
Facial paresis at the initial presentation was found in 32
patients (28 total, 4 partial), equally distributed in male and
female patients. The duration of symptoms in both groups:
with and without facial nerve paresis is shown in Table 1.
The average duration of complaints before the initial pre-
sentation was 16.8 months in the paresis group, and
14.1 months for the non-paresis group. However, the diVer-
ence did not achieve a statistical signiWcance (Mann–Whitney
test: p = 0.121).
Taking into consideration tumor histology, the shortest
duration of symptoms to presentation was found in squa-
mous cell cancers—6.2 months, followed by metastasis to the
parotid—7.8 months, then adenoid cystic carcinoma—15.3
months, and acinic cell cancer after 55 months. The results
were statistically signiWcant (Kruskal–Wallis test:
p < 0.001). There was no statistical diVerence between the
histologic types with regard to the propensity toward facial
nerve paresis. Tumor diameter and occurrence of facial
palsy were compared. Of the 32 patients with paresis, 4
were in tumors <2 cm; 7 in tumors between 2 and 4 cm;
and 21 in tumors >4 cm (Table 2). The correlation between
tumor size and paresis is statistically evident (Chi-quadrate
test p < 0.001).
During the study period, 778 parotidectomies were per-
formed in our institution. Of this group, there were 103
malignancies. Partial lateral parotidectomy was performed
in 37 patients, although the majority of the cases treated by
this technique took place before the year 2000. Between
2001 and 2006, lateral parotidectomies and total parotidec-
tomies were predominantly performed. The analysis of
surgical treatment of parotid malignancies included the
Table 1 Correlation between duration of symptoms and paresis of the
facial nerve at the initial presentation
Paresis of the 
facial nerve
N Duration of symptoms (months)
Mean Standard 
deviation
Minimum Maximum
Yes 32 16.8 17.7 2.0 72.0
No 71 14.1 20.1 1.0 120.0Eur Arch Otorhinolaryngol (2012) 269:1177–1182 1179
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comparison of three diVerent surgical techniques: tumor
removal with a margin of healthy tissue, lateral parotidec-
tomy, and total parotidectomy. In Table 3, the choices of
surgical procedures are presented. In patients with positive
nodes (N+), neck dissection was performed, depending on
the age of the patient, advanced stage of the cancer (T&N),
and the presence of facial nerve palsy. Importantly, this
study compared the selection of three operating techniques:
partial lateral parotidectomy, lateral parotidectomy, and
total parotidectomy. Table 3 analyzes the factors of age,
tumor size, nodal status, and facial nerve status compared
to the choice of operation with or without neck dissection.
There was no diVerence between the age groups when ana-
lyzes by treatment method, T stage, N stage, and facial
nerve palsy. The status of the neck was compared to the
risk of facial paralysis. 27 neck dissections (15 selective
level II and III, and 12 radical) were performed on the 103
patients with parotid malignancies. Pathological examina-
tion of surgical specimens conWrmed metastases in 20
patients (pN+). The positive nodal disease was not identi-
Wed by pathologist in the primary specimen in any patient.
The presence of positive lymph nodes was not a statistically
signiWcant risk factor for facial nerve involvement. Logline
analysis performed for the following factors: the type of
operation, T stage, N stage, nerve palsy, and age (catego-
rized in two groups) revealed that the greatest inXuence on
the chosen type of operation was T stage and facial nerve
palsy. With higher T stage, the number of total parotidecto-
mies performed increased and lateral parotidectomies
decreased; however, this is noticed most clearly in the
group of patients with facial nerve palsy.
Hundred percent of the facial nerve palsy group was
treated by means of total parotidectomy (28 patients) or by
lateral parotidectomy (4 patients). This is compared to the
group without palsy, in which these more extensive proce-
dures account for less than 50% of the surgeries (Table 4).
The correlation is statistically signiWcant (Chi-quadrate
test; p < 0.001). In four patients with facial palsy, lateral
parotidectomy can be explained by the small tumor volume
restricted to the inferior pole of the gland and partial palsy
including only the marginal branch of the facial nerve.
Thus, on presentation, the facial nerve function was in H-B
scale 2, 2, 2, 3, respectively, and only in one patient paresis
progressed (2 ! 3). In Wve patients without clinical evi-
dence of nerve involvement, the neural inWltration was
identiWed intra-operatively. In these patients, the antero-
grade technique was used to identify the main trunk and the
retrograde technique to visualize two distal branches. The
inWltrated segment was resected, and a cable graft was har-
vested for reanimation from the greater auricular nerve.
Thus, in all Wve patients immediately after surgery the dete-
rioration of facial function was striking (1 ! 6), but in four
of them in 1-year time rehabilitation, the improvement was
noticed (6 ! 3,4,4,4). The decision to not reconstruct the
nerve in any of the 32 patients with previous palsy was
made because of diYculties in securing a long enough
proximal stump to perform epineural repair, or inadequate
distal branches. In four patients aged >80, reconstruction
was not performed because of poor general status.
In all patients, pathology was performed and the margins
were assessed. Histological analysis revealed that in 18 out
of 103 cases, free margins were not obtained (resection
margins incomplete or close). This included 8 (25%)
patients with facial nerve paresis and 10 (14%) patients
Table 2 Correlation between tumor size and facial nerve paresis at the
initial presentation
Paresis of 
the facial 
nerve
Tumor size All
<2 cm <4 cm >4 cm
Yes 4 (12.5%) 7 (21.9%) 21 (65.7%) 32 (100.0%)
No 15 (21.1%) 46 (64.8%) 10 (14.1%) 71 (100.0%)
All 19 (18.4%) 53 (51.5%) 31 (30.1%) 103 (100.0%)
Table 3 Treatment methods
Treatment of 
primary tumor
Partial lateral parotidectomy 
37 patients
Lateral parotidectomy 
34 patients
Total parotidectomy 
32 patients
Neck N0 31 Neck dissection 6 N0 28 Neck dissection 6 N0 17 Neck dissection 15
Age
>57 years 17 5 10 2 12 10
<57 years 14 1 18 4 5 5
T T1-19 T1-1 T2-11 T2-3 T3-2 T3-2
T2-12 T2-5 T3-13 T3-3 T4-15 T4-13
T4-4
N N0-31 N0-4 N0-28 N0-1 N0-17 N0-2
N1-2 N1-5 N1-13
Paresis of the facial nerve 0 0 4 0 16 121180 Eur Arch Otorhinolaryngol (2012) 269:1177–1182
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without paresis. The diVerence was not statistically signiW-
cant.
Local-regional control and disease-free survival were
studied in the all of patients with parotid malignancies in a
3-year follow-up.
Local recurrence was observed in 11 out of 103 patients.
This included six (18.8%) patients with facial paresis and in
Wve (7%) patients without. This was not statistically signiW-
cant (Chi-quadrate test; p = 0.075). The data are shown in
Table 5.
Neck node control was 90% for non-paresis patients and
92% for patients with nerve paresis. Distant metastases
were observed in only two patients, both without impaired
nerve function.
The analysis of factors inXuencing the survival in
patients with parotid malignant tumors revealed a statistical
signiWcance for shorter survival in the high tumor stages
(p = 0.014), in high grade histology (p = 0.008), and in
facial paresis before treatment (p = 0.001). Percentage dis-
ease-free 3-year survival diVered dramatically for advanc-
ing tumor (T Stage) and was 85, 90, 70, and 32% for T1,
T2, T3, and T4, respectively (Fig. 1). The percentage dis-
ease-free 3-year survival was 45 and 88% for patients with
and without facial paresis (Fig. 2).
Discussion
The present study describes one center’s 10-year experi-
ence with parotid malignancy treatment with a focus on
facial nerve status. In this retrospective analysis, the
authors have taken into consideration patients’ age, gender,
the duration of complaints (lump and facial paresis), preop-
erative clinical features of the primary (diameter, skin
involvement, total or partial nerve paresis), histologic data,
postoperative assessment of specimens, and outcome mea-
sures (time until relapse and survival).
In the examined group, facial nerve palsy appeared in
nearly 33% of patients (32/103). This included 28 with total
paralysis and 4 with partial paralysis. However, of the
Table 4 Occurance of facial nerve paresis and treatment method
a Facial nerve palsy including only a marginal branch
b Facial nerve resection with immediate reconstruction
Treatment Facial nerve palsy All
Yes No
Partial lateral 
parotidectomy
0 (0.0%) 37 (52.1%) 37 (35.9%)
Lateral parotidectomy 4a (12.5%) 30/1b (42.3%) 34 (33.0%)
Total parotidectomy 28 (87.5%) 4/4b (5.6%) 32 (31.1%)
All 32 (100.0%) 71 (100.0%) 103 (100.0%)
Table 5 Comparison of recurrence frequency in patients with and
without facial nerve paresis
Local 
recurrence
Facial nerve paresis All
Yes No
No 26 (81.3%) 66 (93.0%) 92 (89.3%)
Yes 6 (18.8%) 5 (7.0%) 11 (10.7%)
All 32 (100.0%) 71 (100.0%) 103 (100.0%) Fig. 1 Curve of survival probability depending on tumor stage
according to Kaplan–Meier
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patients with parotid tumors of advanced stage, over 50%
had facial nerve palsy as the presenting and dominant
symptom. Facial nerve palsy was the clinical symptom in
60% of patients with adenoid cystic carcinoma and in 66%
with squamous cell cancer. The paralysis was less frequent
(33.3%) in cancers developing from mixed tumors. Taking
into consideration metastases, O’Brien and co-authors pro-
posed a new staging system for patients with metastatic
squamous carcinoma (SCC) to the parotid irrespective of
cervical nodal status. In a series of 87 patients, metastases
were staged according to the clinical extent of disease in
three groups: P1, tumor up to the 3 cm in diameter; P2,
tumor greater than 3 cm up to 6 cm in diameter or multiple
metastatis parotid nodes; P3, tumor greater than 6 cm in
diameter, VII nerve palsy or skull invasion. Author recom-
mends that the clinical staging system for cutaneous SCC
of the head and neck should separate parotid and neck dis-
ease [9]. The results of this study demonstrated, that
patients with metastatic cutaneous SCC in both the parotid
gland and neck had a signiWcantly worse prognosis than
those with in the parotid alone. These observations were
conWrmed in group of 232 patients by Bron et al. [2] and by
Andruchow et al. [1] in multicenter study of 322 patients
from six diVerent institutions. For metastases to the parotid,
none out of our 12 (100%) patients had a facial palsy. A
similar observation was made by Moriniere et al. [8], who
revealed facial nerve palsy in 33% of primary malignant
tumors and in only 6% of metastasis to the parotid8. In
Terhaard et al.’s [13] analysis describing 324 malignant
tumors of the parotid, 27% of the patients were found with
no facial paresis, 14% were observed with partial paralysis,
and 7% had total paralysis. Preis and co-authors in their
research presented a group of 66 patients. They found 8
patients with facial paralysis and in 16 others the inWltration
was diagnosed intra-operatively. Salivary duct carcinoma
was strongly associated with facial paresis [10].
The assessment of risk factors for facial nerve palsy, in
cases of malignant tumors, was presented by Terhaard et al.
[13]. There was a statistically signiWcant correlation
between facial nerve paralysis and localization in deep
lobe, old age, pain, and inWltration of perineurium. Huang
et al., based on 60 patients with post-operative weakness of
the facial nerve function, showed a signiWcantly higher
risk of paresis in operations for cancers greater than 4 cm.
Post-operative paresis was also higher in patients with
intra-operative signs of nerve inWltration (95.5%) versus no
inWltration (51.3%). The authors mentioned above did not
demonstrate a connection between the histology of the
tumor and the presence of palsy. However, tumor size,
presence in the deep lobe, and nerve inWltration were highly
signiWcant [3]. This is conWrmed by Preis et al., who recog-
nized the location in the deep lobe and the size of the tumor as
important factors. They did not show a correlation with age,
sex, pain, and metastases to lymph nodes [10]. Our research
demonstrated that facial nerve palsy occurs signiWcantly
more in tumors greater than 4 cm. It is well known that
malignant inWltration of the facial nerve happens more fre-
quently with a longer duration of symptoms and an
advanced stage. A longer duration of symptoms and a
delayed initiation of treatment increase the risk of facial
palsy, and worsen the outcome. This was conWrmed in our
research. Despite the fact that the results were not statisti-
cally signiWcant, the duration of symptoms in patients with
facial nerve palsy was nearly 3 months longer than in
patients whose only symptom was a tumor. Non-radical
surgery (positive surgical margins) was more prevalent in
the paretic group (25%) versus the non-paretic group
(14%). Local recurrence was higher in the paresis group
(18.8 vs. 7%). Similar results were presented by
Terhaardet al. They demonstrated that facial nerve palsy
correlated with a signiWcantly lower percentage of survival,
13% for total and 37% for partial paralysis, in comparison
to 69% for patients without paresis [13]. Our study clearly
proved a correlation of both T stage and facial nerve palsy
at presentation and the duration of survival of patients with
parotid cancer.
The quality of life of the patients after radical removal of
the cancer depends on the extent of resection, facial nerve
preservation, and the preservation of neighboring structures
such as the great auricular nerve, hypoglossal nerve, man-
dibular nerve, and the lateral wall of the pharynx [4, 11].
Removal of one or several of the facial nerve branches
leads to long-term functional deWcits, and facial muscle
atrophy Cable graft techniques and neural repair are vital in
the reconstruction and recovery of the resected facial nerve.
Muscle rehabilitation is also important to preserve the mass
of muscles while they are temporarily deprived of motor
innervation [7, 14].
In the study from Holland, among 332 patients, the facial
nerve was sacriWced in 21% of patients, and a reconstruc-
tion was performed in only 1/3 of those with sacriWced
nerves (19/60) [12]. Final results of treatment showed a
partial paresis in 22% of patients and total paresis in 17%.
In our analysis, a reconstruction was performed in Wve
patients. Overall, 32 out of 103 were left with permanent
facial paralysis, with 28 cases involving all three branches.
Conclusion
In our study, the incidence of facial nerve palsy due to
malignant tumors of the parotid was not correlated with age,
sex, duration of symptoms, and histological type of tumors.
However, tumor size had a strong statistical correlation with
paresis and emphasizes the importance of early diagnosis
and treatment to optimize outcome. Facial nerve paresis had1182 Eur Arch Otorhinolaryngol (2012) 269:1177–1182
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a very strong prognostic correlation with a poor outcome in
the treatment of malignant neoplasm of parotid. Similarly, a
high T stage, and a highly malignant histology, both have a
directly negative inXuence on the patients’ survival.
In conclusion, on the basis of analyzed data, prognostic
factors concerning pre-treatment risk of facial paresis did
not show a correlation with gender, age, duration of history,
and tumor histology. However, a longer duration of symp-
toms and a higher grade histology was observed in paresis
group. Increased tumor diameter was the single factor that
was statistically correlated with a risk of facial palsy.
Pre-treatment facial nerve status was prognostically sig-
niWcant. Facial nerve impairment before resection was very
strongly predictive for a shorter disease-free survival.
Facial nerve impairment was correlated with larger tumors
and a higher histologic grade of malignancy.
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